Chlortalidone


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Hypertension
Adult: Initially, 12.5 or 25 mg daily given alone or w/ other antihypertensive; may increase to 50 mg daily if necessary.
Elderly: Initially, 6.25-12.5 mg once daily or on alternate days. Max: 25 mg daily.
Child: Initially, 0.5-1 mg/kg 48 hrly. Max: 1.7 mg/kg 48 hrly.

Oral
Diabetes insipidus
Adult: Initially, 100 mg bid. Maintenance: 50 mg daily.
Child: Initially, 0.5-1 mg/kg 48 hrly. Max: 1.7 mg/kg 48 hrly.

Oral
Oedema, Oedema associated with heart failure
Adult: Initially, 25-50 mg daily given alone or w/ digitalis, ACE inhibitor, or both; may increase to 100-200 mg daily in severe cases. Maintenance: 25-50 mg daily or on alternate days.
Child: Initially, 0.5-1 mg/kg 48 hrly. Max: 1.7 mg/kg 48 hrly.
Suy thận
CrCl (mL/min) Dosage
<30 Contraindicated.
Suy gan
Severe: Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Hypersensitivity to chlortalidone and other sulfonamide derivatives. Anuria, symptomatic hyperuricaemia (i.e. history of gout or uric acid calculi); refractory hypokalaemia, hyponatraemia, and hypercalcaemia; adrenal insufficiency (e.g. Addison’s disease), HTN during pregnancy. Severe hepatic or renal (CrCl <30 mL/min) impairment. Concomitant lithium therapy.
Thận trọng
Patient w/ DM, moderate-high cholesterol level, SLE, history of allergy or bronchial asthma. Patient undergoing surgery. Childn, elderly. Hepatic (e.g. cirrhosis) or renal (e.g. nephrotic syndrome) impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypersensitivity, hypokalaemia, hyperlipidaemia, hyperuricaemia, hyponatraemia, hypomagnesaemia, hypochloremic alkalosis, hyperglycaemia, gout, photosensitivity. Rarely, hypercalcaemia.
Nervous: Dizziness, vertigo.
CV: Postural hypotension.
GI: Mild GI disturbance, loss of appetite.
Genitourinary: Erectile dysfunction.
Dermatologic: Rash, urticaria.
Others: Weakness.
Thông tin tư vấn bệnh nhân
This drug can cause dizziness, if affected, do not drive or operate machinery. Avoid long-term sun exposure.
Chỉ số theo dõi
Monitor BP, serum electrolytes, renal function, wt, and intake/output records (daily to determine fluid loss).
Quá liều
Symptoms: Dizziness, nausea, somnolence, hypovolaemia, hypotension, electrolyte disturbance, cardiac arrhythmia, muscle spasm. Management: Employ gastric lavage or activated charcoal, or induce emesis. Monitor BP, fluid, and electrolytes w/ appropriate corrective measures taken. Admin of IV fluid, electrolyte replacement, and artificial plasma supplementation may be beneficial.
Tương tác
Increased hypokalaemic effect w/ corticosteroids, amphotericin, carbenoxolone, ACTH, and β2-agonists. Reduced diuretic and antihypertensive effects w/ NSAIDs (e.g. indometacin). May increase the effects of antihypertensive agents and curare derivatives. May reduce therapeutic effects of insulin, oral antidiabetic agents, and oral anticoagulants. May induce cardiac arrhythmia w/ digitalis. May increase risk of hyperuricaemia and gout-type complications w/ ciclosporin.
Potentially Fatal: May cause rapid increase in serum lithium levels, leading to toxicity.
Ảnh hưởng đến kết quả xét nghiệm
May increase the para amino benzoic acid (PABA) percentage during bentiromide test.
Tác dụng
Description:
Mechanism of Action: Chlortalidone, a phthalimidine derivative of benzenesulfonamide, has actions similar to thiazide diuretics even though it does not contain a thiazide ring system. It inhibits Na and Cl reabsorption in the cortical-diluting segment of the ascending loop of Henle, thereby leading to increased secretion and excretion of K and hydrogen ions. Additionally, it promotes Ca reabsorption.
Onset: Approx 2.6 hr.
Duration: 48-72 hr.
Pharmacokinetics:
Absorption: Erratically absorbed from the GI tract. Bioavailability: Approx 64%. Time to peak plasma concentration: 8-12 hr.
Distribution: Extensively distributed in erythrocytes. Crosses the placenta and enters breast milk. Plasma protein binding: Approx 75%, 58% to albumin.
Metabolism: Metabolised in the liver.
Excretion: Via urine (approx 70%, mainly as unchanged drug). Elimination half-life: 40-60 hr.
Đặc tính

Chemical Structure Image
Chlortalidone

Source: National Center for Biotechnology Information. PubChem Database. Chlorthalidone, CID=2732, https://pubchem.ncbi.nlm.nih.gov/compound/Chlorthalidone (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C. Protect from light and moisture.
Phân loại MIMS
Thuốc lợi tiểu
Phân loại ATC
C03BA04 - chlortalidone ; Belongs to the class of low-ceiling sulfonamide diuretics.
Tài liệu tham khảo
AFT Pharmaceuticals Ltd. Hygroton 25 mg Tablets data sheet 19 September 2016. Medsafe. http://www.medsafe.govt.nz/. Accessed 22/02/2017.

Anon. Chlorthalidone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/02/2017.

Buckingham R (ed). Chlortalidone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/02/2017.

Joint Formulary Committee. Chlortalidone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/02/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Chlorthalidone. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 22/02/2017.

Preston CL (ed). Lithium + Diuretics; Thiazide and Related. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 24/03/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Chlortalidone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in